Key Points
- The Gamaleya Center in Russia announced that it has developed a melanoma vaccine and is ready for 12 patients.
- The vaccine will move to the clinical trial stage by being administered to at least 20 patients by the end of the year.
- The therapeutic vaccine actively stimulates patients' immune systems to target melanoma cells.
By the Numbers
Alexander Gintsburg, the scientific director of the Gamaleya National Epidemiology and Microbiology Research Center, announced that the melanoma vaccine developed in Russia is currently ready to be administered to at least 12 patients. The vaccine is a therapeutic vaccine designed to stimulate the immune system of melanoma patients against tumor cells. Gintsburg noted that preclinical and phase 1 trials related to the vaccine have yielded positive results. The production of this vaccine is being carried out in the center's existing facilities.
Gintsburg said that work on the vaccine is continuing and that the vaccine will be administered to at least 20 patients in total by the end of this year. Patient selection will focus on those with advanced melanoma and those who do not respond to standard therapies. A process to collect more detailed data on the vaccine's safety and efficacy is being planned. If successful, this approach could be applicable to other skin cancers and possibly different tumor types.
React to this story
Ask about this story
Answers are AI-generated from this story only.
Frequently Asked Questions
- What is the melanoma vaccine and how does it work?
- The melanoma vaccine is a therapeutic vaccine that directs the patient's immune system to recognize and destroy melanoma cells.
- Who will receive the vaccine?
- The initial group consists of 12 patients with advanced melanoma who do not respond to standard treatments; it will be expanded to a total of at least 20 patients by the end of the year.
- What information is available about the vaccine's safety and efficacy?
- The Gamaleya Center stated that preclinical and phase 1 trials yielded positive results regarding safety and immune response; more comprehensive data are being collected.
This is an AI-generated summary. The full story lives at the source.
Read the full story at the sourcerussian.rt.comHow we produce our content →